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ABSTRACT
Introduction: The objective of this review was
to conduct a systematic review with meta-
analysis and Bayesian mixed treatment
comparisons (MTC) evaluating the impact of
biologics on non-Psoriasis Area and Severity
Index (PASI) health outcomes in patients with
moderate-to-severe plaque psoriasis.
Methods: MEDLINE and Cochrane Central
Register of Controlled Trials were searched
from 1966 to May 2009. Citations were screened
for randomized, controlled trials of biologics
versus either placebo or each other in adults
with moderate-to-severe plaque psoriasis and
reported any of several outcomes. Traditional
and Bayesian MTC meta-analyses were
conducted for each endpoint using either a
random- or fixed-effect model where
appropriate.
Results: Thirty-eight studies met eligibility
criteria. All biologics showed significant
improvement in achieving a good response on
the static physician’s global assessment (PGA)
versus placebo while, in the MTC, differences
were noted between individual drugs. In
achieving a good response on the dynamic
PGA, all biologics showed significant
improvements over placebo, while the MTC
showed significant improvements with the anti-
interleukins versus anti-T cells. Relative to
placebo, antitumor necrosis factor (TNF)
agents and anti-interleukins showed
significant improvements in the Dermatology
Life Quality Index (DLQI). Compared with
placebo, the anti-TNF agents showed
significant improvements in both 36-item
Medical Outcomes Study Short-Form General
Health Survey (SF-36) mental and physical
E. L. Baker  C. I. Coleman  K. M. Reinhart 
O. J. Phung  L. Kugelman  W. Chen 
C. M. White  W. L. Baker (&)
Health Outcomes, Policy and Economics (HOPE)
Collaborative Group of the University of
Connecticut School of Pharmacy and Hartford
Hospital, Hartford, CT, USA
e-mail: wbaker@uchc.edu
C. M. Mamolo
Pfizer Inc., Outcomes Research, Groton, CT, USA
J. C. Cappelleri
Pfizer Inc., Statistics, Groton, CT, USA
Enhanced content for this article is
available on the journal web site:
www.dermtherapy-open.com
123
Dermatol Ther (2012) 2:9
DOI 10.1007/s13555-012-0009-3
component scores, while anti-T cell agents
showed no improvements. The MTC showed
no differences between any biologics for either
the DLQI or SF-36.
Conclusion: Individual biologics and classes
showed consistent benefits across non-PASI
health outcomes in patients with moderate-to-
severe plaque psoriasis while MTC meta-
analyses suggested that some differences exist.
Keywords: Biologics; Meta-analysis; Plaque
psoriasis
INTRODUCTION
Psoriasis is a chronic inflammatory disorder
seen in approximately 2–3% of the world’s
population, affecting the skin and often joints.
The most common form is plaque psoriasis,
which appears as sharply demarcated,
erythematous areas covered with silvery-white
scale [1, 2]. The formation of psoriatic plaques
involves the interplay of T cells, cytokines, and
keratinocytes. The presence of activated T cells
within psoriatic plaques and the response to
T cell-directed therapy suggest an immunologic
nature of the disease [3, 4]. Various cytokines,
such as tumor necrosis factor alpha (TNFa), are
also present in psoriatic lesions, and may be a
target for drug therapy [5]. Both cytokines and
activated T cells promote the dysregulated
growth of keratinocytes, leading to patches of
erythematous, scaly skin.
Although there is no cure, treatment is
directed at decreasing the signs and symptoms
of psoriasis and modifying the natural
progression of the disease. Methotrexate and
cyclosporine are systemic agents that have
proven efficacy but are limited by various
toxicities including liver and kidney
complications [1]. Numerous other systemic
biologic agents are available and are
categorized into three classes: anti-T cell
agents (efalizumab, which was removed from
the United States market in 2009, and
alefacept), anti-TNF agents (infliximab,
adalimumab, and etanercept), and anti-
interleukin (IL)-12/23 agents (ustekinumab
and an investigational agent briakinumab) [6].
Prior meta-analyses have demonstrated the
benefits of these agents on various outcomes in
moderate-to-severe plaque psoriasis [7, 8]. This
includes studies of the Psoriasis Area and
Severity Index (PASI), a traditionally reported
endpoint in this area [8]. However, none have
comprehensively evaluated the impact of
biologics on the physician’s global assessment
(PGA) or assessments of health-related quality
of life (HRQoL). Thus, the authors conducted a
systematic review with meta-analysis and
Bayesian mixed treatment comparisons (MTC)
evaluating the impact of biologics on health
outcomes, including the PGA and patient-




Two independent investigators conducted
systematic literature searches of MEDLINE
(1966 to May 2009) using the Cochrane
Highly Sensitive and specific Search Strategy
(Sensitivity and Precision Maximizing Version
2008) [9], and the Cochrane Central Register of
Controlled Trials (1966 to May 2009). The
following Medical Subject Heading and
text keywords were used: psoriasis, plaque
psoriasis, etanercept, infliximab, adalimumab,
efalizumab, alefacept, ustekinumab, ABT-874
(briakinumab), T cell modulator, monoclonal
Page 2 of 20 Dermatol Ther (2012) 2:9
123
antibody, tumor necrosis factor, biologic agent,
and biologics.
Study Selection
Studies were included in the evaluation if they
were (1) randomized, controlled trials (RCTs) of
biologic agents to treat psoriasis versus placebo
or each other; (2) conducted in adult patients
with moderate-to-severe plaque psoriasis,
usually defined as having an inadequate
response to topical treatments alone and
either having received prior systemic therapy
or are candidates for such therapy; and (3)
studies that reported efficacy data on clinical or
humanistic outcomes. A Preferred Reporting
Items for Systematic Reviews and Meta-
Analyses (PRISMA) diagram was constructed
for the literature search and selection process
to describe the number of citations identified,
studies excluded, and studies ultimately
included (Fig. 1) [10].
Validity Assessment
All studies were reviewed and evaluated by two
reviewers with disagreement resolved by
discussion. The validated Jadad scale was used
to assess the methodological quality of included
trials [11]. This rating scale assesses inherent
controllers of bias by using the following
quality assessment criteria: use of and methods
for generating randomization; use of and
methods for double-blinding; and description
of patient withdrawals and dropouts. One point
was given for each satisfied criterion. An
aggregate score between 0 and 5 was
calculated for each included trial (0 = weakest,
5 = strongest), with trials scoring\3 deemed to
have lower methodological quality.
Data Abstraction
Through use of a standardized data abstraction
tool, two reviewers independently collected data,
with disagreement resolved through discussion
or triage to a third reviewer. The following
information was obtained from each trial:
author identification, year of publication, study
design and above-mentioned methodological
quality criteria, source of study funding, study
population, patient demographics, and
co-morbidities.
Study Endpoints
The first endpoint is the PGA, which can be
reported as either a static or dynamic scale [12].
There is no standard PGA, and different
versions include six- or seven-point scales,
which measure the severity of psoriasis. Terms
such as ‘‘clear’’ or ‘‘excellent’’ (scores of 0 or 1)
are used to define the clearing of psoriatic
plaques from the skin, with higher scores
denoting more severe disease. To measure
HRQoL, two scales are used. The first is the
(acute or chronic version) 36-item Medical
Outcomes Study Short-Form General Health
Survey (SF-36). It measures eight domains of
HRQoL (physical function, social function,
pain, physical and emotional role limitation,
vitality, personal perceptions of health, and
emotional well-being). Normal scores have a
mean of 50, with higher scores being more
favorable. The second is the Dermatology Life
Quality Index (DLQI), a 10-item questionnaire
that assesses the impact of chronic skin
conditions on HRQoL, and is frequently used
in clinical trials of psoriasis [13]. Scores range
from 0 to 30, with 0 representing no disease
impact on HRQoL.
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Statistical Analysis
Traditional meta-analysis was initially
performed. For the primary analyses, only the
US Food and Drug Administration (FDA)-
approved doses for each agent were included
(for briakinumab, the investigational doses were
included). In an attempt to avoid double-
counting individual agents in the analyses,
when studies investigated more than one FDA-
approved dose, only the highest dose was
included in an analysis. This rule was not
applied to either ustekinumab or briakinumab,
which were not FDA-approved at the time this
protocol was developed. Sensitivity analyses
were also performed whereby data from all
studies were included, regardless of dose. For
dichotomous endpoints, weighted averages
were reported as odds ratios (ORs) with
associated 95% CIs using a DerSimonian and
Laird random-effects model [14]. For traditional
meta-analysis for continuous outcomes,
Fig. 1 Flow diagram of study selection. PGA physician’s global assessment
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weighted averages were reported using a
difference between means, with associated
95% CIs using a DerSimonian and Laird
random-effects model [14].
Statistical heterogeneity was addressed using
the I2 statistic, which assesses the degree of
inconsistency across studies and ranges from 0%
to 100% with the higher percentage representing
a higher likelihood of the existence of
heterogeneity [15]. Visual inspection of funnel
plots and Egger’s weighted regression statistics
were used to assess for the presence of
publication bias [16, 17]. Statistics were
performed using StatsDirect statistical software,
version 2.4.6 (StatsDirect Ltd., Cheshire, UK) and
Comprehensive Meta-Analysis, Version 2
(Biostat, Englewood, NJ, USA). A P value of
\0.05 was considered statistically significant for
all analyses.
In addition to traditional meta-analysis, a
MTC meta-analysis was conducted using
previously validated WinBUGS code [18–22].
MTC methods were used to compare the
different biologic agents to treat plaque
psoriasis. These methods are a generalization
of meta-analysis methods because they allow
comparisons of agents not addressed within any
of the individual trials. A random-effects model
was fitted, taking into account the correlation
structure induced by multi-arm trials. All MTC
analyses were conducted using a Bayesian
Markov chain Monte Carlo method and fitted




A total of 1,287 citations were identified
through the MEDLINE, Cochrane Central,
and manual reference searches (Fig. 1). Of these,
31 studies were identified describing the following
comparisons (Table 1) [23–53]: alefacept versus
placebo (n = 5) [23–27]; efalizumab versus placebo
(n = 7) [28–34]; infliximab versus placebo (n = 6)
[35–40]; adalimumab versus placebo (n = 5) [41–
45]; etanercept versus placebo (n = 4) [46–49];
ustekinumab versus placebo (n = 3) [50, 51];
briakinumab versus placebo (n = 1) [53]. A total
of 20 studies were included in the statistical
analyses and evaluated FDA-approved doses:
alefacept (n = 2) [26, 27], efalizumab (n = 4)
[31–34], infliximab (n = 3) [36–38],
adalimumab (n = 4) [41, 42, 44, 45], etanercept
(n = 3) [46–48], ustekinumab (n = 3) [50–52],
briakinumab (n = 1) [53].
PGA Static Response Rate
Sixteen RCTs evaluating seven drugs from three
classes reported data on the PGA response rate
using a static scale (Table 2) [23, 24, 27, 31, 33,
34, 36, 38, 42, 45–49, 51–53]. All of the RCTs
were of high quality (Jadad C4) and ranged from
8 to 24 weeks in duration. Ten studies [31, 33,
34, 36, 38, 42, 45, 51–53] defined their endpoint
using a scale of ‘‘clear’’ or ‘‘minimal’’ rating
while the remaining six studies [23, 24, 27, 46,
48, 49] used a scale of ‘‘clear’’ or ‘‘almost
clear.’’
Six RCTs evaluated the anti-T cell agents
with a single alefacept study [27] and three
efalizumab studies [31, 33, 34] reporting results
using FDA-approved doses. Seven RCTs
evaluated the anti-TNF agents with two
infliximab studies [36, 38], two adalimumab
studies [42, 45], and two etanercept studies
[46, 48] evaluating FDA-approved doses. Three
RCTs evaluating the anti-IL-12/23 agents were
included. Two ustekinumab studies [51, 52]
reported results using the FDA-approved dose
and the maximally effective dose of
Dermatol Ther (2012) 2:9 Page 5 of 20
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Table 1 Included study characteristics
Study, ref Years Study duration
(weeks)
Comparison N Baseline PASI Jadad
Score
Alefacept
Ellis et al. [23] 2001 12 ALA 0.025 mg/kg IV QW 57 14 (4–45)a 5
ALA 0.075 mg/kg IV QW 55 15 (4–45)a
ALA 0.150 mg/kg IV QW 58 20 (7–33)a
Placebo 59 15 (3–72)a
Gordon et al. [24] 2003 12 ALA 7.5 mg IV QW 367 14.4–15.9 5
Feldman et al. [25] 2004 Placebo 186 15.1
Finlayet al. [26] 2003 12 ALA 10 mg IM QW 173 15.1 (3.4–58.8) 5
Lebwohlet al. [27] 2003 14 ALA 15 mg IM QW 168 13.2 (3.7–52.8)
Placebo 168 14.3 (5.3–44.8)
Efalizumab
Papp et al. [28] 2001 8 EFA 0.1 mg/kg IV QW 22 18.2 ± 6.7 4
EFA 0.3 mg/kg IV QW 75 19.1 ± 7.3
Placebo 48 16.2 ± 4.4
Gordon et al. [29] 2003 12 EFA 1 mg/kg SQ QW 369 19.4 (10.1–58.7)a 4
Menter et al. [30] 2005 Placebo 187 19.4 (11.4–50.3)a
Leonardi et al. [31] 2005 12 EFA 1 mg/kg SQ QW 160 18.6 (11.9–50.1)b 5
EFA 2 mg/kg SQ QW 166 18.9 (10–55.6)b
Placebo 170 19.0 (9.6–57.6)b
Ortone et al. [32] 2005 12 EFA 1 mg/kg SQ QW 529 23.6 ± 9.7 5
Dubertret et al. [33] 2006 Placebo 264 23.0 ± 9.6
Papp et al. [34] 2006 12 EFA 1 mg/kg SQ QW 450 19.1 ± 7.5 5
Placebo 236 18.7 ± 7.0
Inﬂiximab
Chaudhari et al. [35] 2001 10 INF 5 mg/kg IVc 11 22.1 ± 11.5 5
INF 10 mg/kg IV 11 26.6 ± 10.3
Placebo 11 20.3 ± 5.5
Gottleib et al. [36] 2004 10 INF 3 mg/kg IVc 99 20 (15, 26)d 5
Feldman et al. [37] 2005 INF 5 mg/kg IV 99 20 (14, 28)d
Placebo 51 18 (15, 27)d
Reich et al. [38] 2005 24 INF 5 mg/kg IVc 301 22.9 ± 9.3 4
Placebo 77 22.8 ± 8.7
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Table 1 continued
Study, ref Years Study duration
(weeks)
Comparison N Baseline PASI Jadad
Score
Menter et al. [39] 2007 10 INF 3 mg/kg IVc 313 20.1 ± 7.9 5
Feldman et al. [40] 2008 INF 5 mg/kg IV 314 20.4 ± 7.5
Placebo 208 19.8 ± 7.7
Adalimumab
Revicki et al. [41] 2007 16 ADA 40 mg SQ QOW 814 19.0 ± 7.1 5
Menter et al. [42] 2008 Placebo 397 18.8 ± 7.1
Shikiar et al. [43] 2007 12 ADA 40 mg SQ QOW 45 16.7 (5.4–39.0)a 4
ADA 40 mg SQ QW 50 14.5 (2.3–42.4)a
Placebo 52 16.0 (5.5–40.4)a
Revicki et al. [44] 2008 16 ADA 40 mg SQ QOW 110 19.4 ± 7.4 5
Saurat et al. [45] 2008 Placebo 53 19.2 ± 6.9
Etanercept
Leonardi et al. [46] 2003 12 ETA 25 mg SQ QW 160 19.3 ± 11.4 4
ETA 25 mg SQ BIW 162 18.5 ± 11.5
ETA 50 mg SQ BIW 164 18.6 ± 11.5
Placebo 166 18.4 ± 11.6
Krueger et al. [47] 2005 12 ETA 25 mg SQ BIW 196 19.1 ± 8.2 5
Papp et al. [48] 2005 ETA 50 mg SQ BIW 194 19.5 ± 8.8
Placebo 193 18.6 ± 8.6
Van de Kerkhof
et al. [49]
2008 12 ETA 50 mg SQ QW 96 21.4 ± 9.3 4
Placebo 46 21.0 ± 8.7
Ustekinumab
Krueger et al. [50] 2007 12 UST 45 mg SQ X1 64 19.0 ± 7.4 4
UST 45 mg
SQ QW X4
64 18.9 ± 7.0
UST 90 mg SQ X1 64 18.8 ± 7.3
UST 90 mg SQ QW X4 64 19.0 ± 7.9
Placebo 64 19.9 ± 8.3
Leonardi et al. [51] 2008 12 UST 45 mg SQe 255 20.5 ± 8.6 5
UST 90 mg SQ 256 19.7 ± 7.6
Placebo 255 20.4 ± 8.6
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briakinumab (200 mg every other week) was
reported in another study [53].
Each individual agent, as well as each class,
showed an increase in the odds of achieving a
positive response (Fig. 2) [27, 31, 33, 34, 36, 38,
42, 45, 46, 48, 51–53]. When all anti-T cell agent
RCTs (OR 5.89, 95% CI 4.34–7.99) and anti-TNF
agent RCTs (OR 24.27, 95% CI 15.66–37.61)
were pooled, regardless of dose, slightly smaller
overall effects were seen.
The MTC analysis included data from 13 trials
of seven therapies in three drug classes that
reported data on the PGA response rate using a
static scale and included arms using the FDA-
approved dose (Tables 3, 4) [27, 31, 33, 34, 36,
38, 42, 43, 46, 48, 51–53]. The placebo-based
comparisons were similar to those discussed
above, although generally had wider credible
intervals (CrI). When the drug classes were
analyzed, both the anti-TNF agents (OR 6.19,
95% CrI 2.75–12.87) and anti-IL-12/23 agents
(OR 7.60, 95% CrI 3.25–18.80) were suggested to
be superior to the anti-T cell agents. Pair-wise
drug comparisons followed similar trends with
many anti-TNF and anti-IL-12/23 agents
showing superior results to the anti-T cell agents.
PGA Dynamic Response Rate
Seven RCTs evaluating three drugs from three
classes reported data on the PGA response rate
using a dynamic scale (Table 2) [28, 29, 31, 33,
35, 39, 50]. All of the RCTs were of high quality
(Jadad C4) and ranged from 10 to 12 weeks in
duration. All of the studies defined their
endpoint using a rating of ‘‘clear’’ or ‘‘excellent.’’
Efalizumab was the only anti-T cell agent
that provided data on the PGA dynamic
Table 1 continued
Study, ref Years Study duration
(weeks)
Comparison N Baseline PASI Jadad
Score
Papp et al. [52] 2008 12 UST 45 mg SQe 409 19.4 ± 6.8 4
UST 90 mg SQ 411 20.1 ± 7.5
Placebo 410 19.4 ± 7.5
Briakinumab
Kimball et al. [53] 2008 12 BRI 100 mg SQ QOW 30 20.0 ± 6.9 4
BRI 200 mg SQ X1 30 18.0 ± 6.7
BRI 200 mg SQ QW X4 30 20.0 ± 7.6
BRI 200 mg SQ QOW 30 20.0 ± 6.2
BRI 200 mg SQ 30 19.0 ± 6.3
QW X12 30 16.0 ± 2.9
ADA adalimumab, ALA alefacept, BIW twice weekly, BRI briakinumab, EFA efalizumab, ETA etanercept, INF inﬂiximab,




c At weeks 0, 2, and 6
d Median (interquartile range)
e At weeks 0, 4, then every 12 weeks
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endpoint with three RCTs evaluating
FDA-approved doses [28, 29, 31, 33]. Infliximab
was the only anti-TNF agent that reported data
on this endpoint, with two RCTs evaluating
FDA-approved doses [35, 39]. Ustekinumab was
the only anti-IL-12/23 agent that reported data on
this endpoint [50].
Each individual agent, as well as each class,
showed an increase in the odds of achieving a
positive response (Fig. 3) [24, 31, 33, 35, 39, 50].
When all anti-T cell agent RCTs (OR 9.73, 95%
CI 6.54–14.49) and anti-TNF agent RCTs (OR
140.58, 95% CI 39.14–504.97) were pooled,
regardless of dose, similar overall effects were
seen.
The MTC analysis included data from six
RCTs of three therapies in three drug classes
that reported data on the PGA response rate
using a dynamic scale and included arms using
the FDA-approved dose [29, 31, 33, 35, 39, 50].
Due to the small numbers of studies included in
the analysis, many indirect comparisons yielded
unreliable results (Tables 3, 4). As a class, the
anti-TNF agents were suggested to be superior to
the anti-T cell agents (OR 22.53, 95% CrI
2.61–206.3).
Change in DLQI from Baseline
Fifteen RCTs evaluating six drugs from three
classes reported data on the change in DLQI score
from baseline (Table 2) [23, 25, 26, 30, 32, 37, 38,
40, 41, 43, 47, 49–52]. All of the RCTs were of high
quality (Jadad C4) and ranged from 10 to
24 weeks in duration. A lower score on the DLQI
represents an improvement, with a score of 0
Fig. 2 Impact of biologic agents on static PGA response rate. IL interleukin, PGA physician’s global assessment,
TNF tumor necrosis factor
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suggesting no impact of the disease on the
patients’ HRQoL scores.
Five RCTs evaluated the anti-T cell agents,
with one alefacept study [26], and two
efalizumab studies [30, 32] reporting results
using FDA-approved doses. Seven RCTs
evaluated the anti-TNF agents, with three
infliximab studies [37, 38, 40], two
adalimumab studies [41–43], and one
etanercept study [47] reporting results using
FDA-approved doses. Ustekinumab was the only
anti-IL-12/23 agent that reported data on this
endpoint with two studies reporting results
using FDA-approved doses [50–52].
The anti-T cell agents as a class, as well as
efalizumab alone significantly reduced the DLQI
score from baseline (Fig. 4). No significant effect
was seen with alefacept alone. Each individual
anti-TNF agent, as well as the pooled class,
significantly reduced the DLQI score from
baseline. Similar effects were seen with
ustekinumab. When all anti-T cell agent RCTs
(WMD -2.377, 95% CI -3.286 to -1.469), anti-
TNF agent RCTs (WMD -8.03, 95% CI -9.24 to
-6.81), and anti-IL-12/23 RCTs (WMD -7.94,
95% CI -8.83 to -7.05) were pooled, regardless
of dose, similar overall effects were seen.
The MTC analysis included data from seven
RCTs of six therapies in three drug classes that
reported data on the change from baseline in
DLQI score and included arms using the FDA-
approved dose (Tables 3, 4) [26, 30, 32, 37, 38,
40, 41, 43, 47, 51, 52]. As above, the placebo-
controlled comparisons were similar between
the MTC and traditional meta-analysis models.
When the drug classes were compared, both the
anti-TNF agents (mean difference -7.77, 95%
CrI -8.27 to -3.23) and anti-IL-12/23 agents
(mean difference -5.37, 95% CrI -7.89 to
-2.82) reduced the DLQI to a greater extent
than the anti-T cell agents. Many of the
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Change in SF-36 from Baseline
Eight RCTs evaluating four drugs from two
classes reported data on the change in SF-36
score from baseline (Table 2) [23, 25, 26, 38, 40,
41, 43, 47]. There were two component scores
examined in this category, the physical and
mental component summary (PCS and MCS)
scores. All of the RCTs were of high quality (Jadad
C4) and ranged from 10 to 24 weeks in duration.
Alefacept was the only anti-T cell agent that
reported data on these endpoints [23, 25, 26],
with a single RCT [26] reporting results using
FDA-approved doses. Five RCTs evaluated the
anti-TNF agents, including infliximab [38–40],
adalimumab [41, 43], and etanercept [47], all of
which reported results using FDA-approved
doses. No anti-IL-12/23 agent studies reported
data on the SF-36 MCS or PCS.
Whereas alefacept had no significant impact
on either the SF-36 MCS or PCS (Figs. 5, 6), each
anti-TNF agent as well as the class significantly
improved both SF-36 endpoints from baseline.
When all anti-T cell agent RCTs (MCS = WMD
2.18, 95% CI -1.61 to 5.97; PCS = WMD 1.95,
95% CI -1.44 to 5.34), and anti-TNF agent RCTs
(MCS = WMD 4.56, 95% CI 3.59–5.54;
PCS = WMD 3.93, 95% CI 3.09–4.78) were
pooled, regardless of dose, similar overall effects
were seen.
The MTC analysis included data from seven
trials of three therapies in two drug classes that
reported data on the change in SF-36 scores (both
MCS and PCS) from baseline using the FDA-
approved dose (Tables 3, 4) [23, 25, 26, 38, 40,
41, 43]. No differences between individual agents
or drug classes were seen in the MTC model.
Statistical Heterogeneity/Publication Bias
Significant statistical heterogeneity was seen
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analysis (I2 = 59.8%), and the anti-TNF class for
the DLQI analysis (I2 = 84.2%). In each case, the
statistical heterogeneity was likely due to
differences in the magnitude of effect rather
than directionality. All other analyses had
no significant heterogeneity (I2\25%),
Fig. 3 Impact of biologic agents on dynamic PGA response rate. IL interleukin, PGA physician’s global assessment,
TNF tumor necrosis factor
Fig. 4 Impact of biologic agents on change in DLQI from baseline. DLQI Dermatology Life Quality Index, IL interleukin,
TNF tumor necrosis factor
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although many analyses had too few studies to
formally test for its presence. Similarly,
publication bias was not statistically significant
in any analysis where enough studies were
included for it to be tested (Egger’s P[0.05 for all).
DISCUSSION
Overall, biologic agents were shown to be
effective for improving clinical psoriasis
symptoms (static and dynamic PGA), as well as
measures of health-related quality of life (DLQI
and SF-36). However, differences between drug
classes and individual agents were seen using a
MTC meta-analytic model. Although each
individual agent and drug class showed
significant improvements in the PGA (static
and dynamic), the MTC model suggested that
the anti-TNF agents and anti-IL 12/23 agents
were both significantly better than the anti-T
cell agents. Individual indirect drug
comparisons showed similar trends. Each
pharmacologic agent and drug class also
showed significant improvements in the DLQI
from baseline with the MTC model showing
Fig. 5 Impact of biologic agents on change in SF-36 MCS from baseline.MCS mental component summary, SF-36 36-item
Medical Outcomes Study Short-Form General Health Survey, TNF tumor necrosis factor
Fig. 6 Impact of biologic agents on change in SF-36 PCS from baseline. PCS physical component summary, SF-36 36-item
Medical Outcomes Study Short-Form General Health Survey, TNF tumor necrosis factor
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similar results to the PGA analysis. Studies have
established that at least a five-point change in
the DLQI can be considered clinically
significant, indicating patients are a little better
orworse [13].Largerchangesare required for more
pronounced clinical improvements. Significant
differences between individual agents ranged
from three to seven points, and between classes
from five to six points. Thus it can be debated that
the differences seen equate to minimal clinical
improvements in DLQI from one agent or class to
the next.
Although the PASI is the outcome most
commonly reported in efficacy clinical trials
for biologic agents in chronic plaque psoriasis,
many regulatory agencies have stressed the
importance of patient-related outcome
measures for their approval process [54]. Since
prior meta-analyses have reported on the
comparative effectiveness of biologics in
patients with plaque psoriasis using PASI [8],
the authors felt it was important to concentrate
on other outcomes of interest, including the PGA
and various HRQoL measures. This makes the
information from our analyses pertinent to both
practicing clinicians as well as regulatory bodies
makingdrugcoveragedecisions.Moreover, studies
evaluating the association between improvements
in PASI with patient-related outcomes have been
inconsistent [55, 56], with more recent data
showing only a mild correlation [56].
Traditional meta-analyses showed that the
anti-T cell agents did not have an impact on the
SF-36 whereas improvements in both the MCS and
PCS were seen with the anti-TNF agents. No
significant effects were seen in the MTC model.
These results are all intriguing, especially given
that the MTC model showed similar point
estimates to traditional meta-analysis for the
direct placebo comparisons. This suggests that
the Bayesian models used were reliable giving
higher credence to the indirect comparison results.
The traditional meta-analysis results from
this review are similar to those of prior
published reports [7, 8, 57, 58]. Additionally,
this meta-analysis is the only one to utilize
Bayesian MTC methodologies to provide
indirect-comparisons between agents in
addition to classes on non-PASI endpoints.
This allows us to estimate the comparative
treatment effects of available biologics and
potentially guide treatment decisions in the
absence of direct studies. The prior meta-
analysis by Reich and colleagues used a
Bayesian hierarchical model and concluded
that no differences between the biologic agents
existed at 24 weeks using the PASI 50, 75, or 90
[57]. No indirect comparisons were made by
class. When compared with placebo, their
results suggest the largest benefit with
infliximab and etanercept versus other agents
such as efalizumab and alefacept on the PASI 75.
Current guidelines from the American
Academy of Dermatology, published in 2008,
state that either an anti-T cell or anti-TNF agent
canbeusedwhenabiologicagent is indicatedwith
no preference given to any particular agent [1].
More recently published guidelines from the
Deutsche Dermatologische Gesellschaft and the
Berufsverband Deutscher Dermatologen in 2011
suggest that the anti-TNF agents (particularly
adalimumab or infliximab) or ustekinumab
should be the biologics of first choice in patients
with psoriasis [59]. The choice of which anti-TNF
agent to use should be patient specific and based
on clinical need. The recommendations state that
patients with stable chronic plaque psoriasis could
consider etanercept or adalimumab as first choice
due to their ease of administration (self
subcutaneous injection). Because of the relatively
new status of the anti-IL 12/23 agents, particularly
ustekinumab, their use is recommended to be
reserved as a second-line biologic agent if anti-TNF
therapy has failed or cannot be used. Our results
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support these recommendations by showing that
anti-TNF agents, as well as anti-IL 12/23 agents,
significantly improve clinical efficacy (via the
PGA) and HRQoL (via the DLQI) as compared
with the anti-T cell agents in patients with
moderate-to-severe plaque psoriasis. It is also
worth noting that the choice of biologic of
preference in some countries, such as the UK,
incorporates both clinical as well as
pharmacoeconomic considerations into their
ranking of agents. The present study did not
evaluate cost-effectiveness, and thus the authors
cannot comment on this further.
The results of this meta-analysis must be
interpreted cautiously as various limitations
exist. Common limitations seen with traditional
meta-analyses include heterogeneity and
publication bias. Due to the low number of
studies included in many of the analyses,
statistical heterogeneity and publication bias
could not be determined. A few analyses
included a moderate degree of heterogeneity
(I2 = 50–75%). Often the differences seen were
related to the magnitude of the effect rather than
its direction. Thus, it is unlikely that this
heterogeneity significantly altered the
conclusions of this review. Differences in the
included studies could have also contributed to
both clinical as well as statistical heterogeneity.
Studies varied by the severity of patients included
(as measured by the baseline PASI score), duration
of studies (ranging from 8 to 24 weeks), study
quality (as assessed using the Jadad score), and
inherent differences between the agents
themselves. All of the studies included in this
review were of high quality (Jadad C4), and the
inclusion of only the FDA-approved doses of the
drugs into the primary analyses was done in an
attempt to provide a somewhat homogeneous
sample.
Similar to heterogeneity, publication bias
could not be assessed in many analyses due to
low study numbers. When it was available,
publication bias was not likely due to an
Egger’s weighted regression statistic P[0.05.
The systematic nature of this literature search, in
addition to the relatively tight inclusion criteria,
likely lead to the lack of publication bias.
Lastly, the short-term nature of many of the
studies included in this review precludes
extrapolation of our results to patients
requiring long-term therapy. Although
estimates from the MTC meta-analysis cannot
simply be assumed accurate, were considered
valid due, in part, to the similar results seen in
the placebo-controlled comparisons between
the MTC and traditional meta-analytic models.
Various knowledge gaps have been identified
by this review. It is clear that comparative
effectiveness studies evaluating the impact of
biologics continue to be required. When these
studies are designed and carried out it should be
required that measures of HRQoL are collected
and reported. In addition, comparative studies
should be of a sufficient duration. As previously
stated, most of the studies included in this
review were 8–24 weeks in duration. Some
included non-randomized 52-week extension
studies that provided safety and efficacy data in
an observational manner. Studies of a year
or more in duration should maintain
randomization in order to confirm whether
differences seen between groups are seen over
the long term.
CONCLUSION
Individual biologics and classes showed
consistent benefits across health outcomes in
patients with moderate-to-severe plaque
psoriasis while MTC meta-analysis suggested
that some differences exist. This work provides
an important channel in the planning of future
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clinical trials aimed at defining the most
efficacious biologic therapy.
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